mebendazole and Liver Neoplasms studies

mebendazole and Liver Neoplasms

mebendazole has been researched along with Liver Neoplasms in 3 studies

Mebendazole: A benzimidazole that acts by interfering with CARBOHYDRATE METABOLISM and inhibiting polymerization of MICROTUBULES.
mebendazole : A carbamate ester that is methyl 1H-benzimidazol-2-ylcarbamate substituted by a benzoyl group at position 5.

Liver Neoplasms: Tumors or cancer of the LIVER.

Research Excerpts

Excerpt	Relevance	Reference
"Sorafenib (SO) is a multi-kinase inhibitor that targets upstream signals in the MAPK pathway."	5.51	Mebendazole augments sensitivity to sorafenib by targeting MAPK and BCL-2 signalling in n-nitrosodiethylamine-induced murine hepatocellular carcinoma. ( Ghanim, AMH; Saber, S; Younis, NS, 2019)
"Sorafenib (SO) is a multi-kinase inhibitor that targets upstream signals in the MAPK pathway."	1.51	Mebendazole augments sensitivity to sorafenib by targeting MAPK and BCL-2 signalling in n-nitrosodiethylamine-induced murine hepatocellular carcinoma. ( Ghanim, AMH; Saber, S; Younis, NS, 2019)
"Mebendazole treatment was begun."	1.36	[Hepatocellular carcinoma complicated with echinococcal cyst of the liver]. ( Dragnev, N; Kobakov, G; Kostov, D; Patanov, R, 2010)

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (33.33)	29.6817
2010's	2 (66.67)	24.3611
2020's	0 (0.00)	2.80

Timeframe

Studies, this research(%)

All Research%

pre-1990

0 (0.00)

18.7374

1990's

0 (0.00)

18.2507

2000's

1 (33.33)

29.6817

2010's

2 (66.67)

24.3611

2020's

0 (0.00)

2.80

Authors

Authors	Studies
Younis, NS	1
Ghanim, AMH	1
Saber, S	1
Kostov, D	1
Dragnev, N	1
Patanov, R	1
Kobakov, G	1
Zöld, E	1
Barta, Z	1
Zeher, M	1

Studies

Younis, NS

Ghanim, AMH

Saber, S

Kostov, D

Dragnev, N

Patanov, R

Kobakov, G

Zöld, E

Barta, Z

Zeher, M

Other Studies

3 other studies available for mebendazole and Liver Neoplasms

Article	Year
Mebendazole augments sensitivity to sorafenib by targeting MAPK and BCL-2 signalling in n-nitrosodiethylamine-induced murine hepatocellular carcinoma. Scientific reports, 2019, 12-13, Volume: 9, Issue:1 Topics: Alanine Transaminase; Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cyclin D1; Diethyln	2019
[Hepatocellular carcinoma complicated with echinococcal cyst of the liver]. Khirurgiia, 2010, Issue:4-5 Topics: Animals; Antinematodal Agents; Carcinoma, Hepatocellular; Cysts; Echinococcosis; Echinococcus; Femal	2010
Hydatid disease of the liver and associated hepatocellular carcinoma. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2005, Volume: 3, Issue:8 Topics: Antinematodal Agents; Carcinoma, Hepatocellular; Echinococcosis; Echinococcus granulosus; Fatal Outc	2005

Article

Year

Mebendazole augments sensitivity to sorafenib by targeting MAPK and BCL-2 signalling in n-nitrosodiethylamine-induced murine hepatocellular carcinoma.

Scientific reports, 2019, 12-13, Volume: 9, Issue:1

Topics: Alanine Transaminase; Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cyclin D1; Diethyln

2019

[Hepatocellular carcinoma complicated with echinococcal cyst of the liver].

Khirurgiia, 2010, Issue:4-5

Topics: Animals; Antinematodal Agents; Carcinoma, Hepatocellular; Cysts; Echinococcosis; Echinococcus; Femal

2010

Hydatid disease of the liver and associated hepatocellular carcinoma.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2005, Volume: 3, Issue:8

Topics: Antinematodal Agents; Carcinoma, Hepatocellular; Echinococcosis; Echinococcus granulosus; Fatal Outc

2005